Our findings differ with previous institution investigations that looked at the immunological reaction following immunization in two additional user groups that weren’t included in the COVID-19 vaccines medical research: organs transplantation users & individuals suffering rheumatic & musculoskeletal illnesses.  

COVID-19 Vaccine Likely Protects HIV Patients

According to experts who participated in this research the level of immunity increases with different vaccines that are used to counter the spread of the virus. It is a known fact that among these patients the level of immunity seriously decreases and hence they cannot bear ordinary infections also. The vaccines made for Covid-19 can help them improve the overall immunity level. This fact was researched on several patients by experts and they displayed their observations.

Following 2 injections of the viruses, all subgroups had lower-than-normal antibodies concentrations, and it was only after a third shot that transplanted patients are capable of developing an efficient defense.

COVID-19 Vaccine Likely Protects HIV Patients

Individuals infected with HIV are expected to be safeguarded from SARS-CoV-2, the virus that causes COVID-19 provided they were completely vaccinated, according to a Johns Hopkins Medicine study team.

The research of HIV-positive individuals is reported in the journal Clinical Infectious Diseases on July 22, 2021.

“Previous research has suggested a suboptimal response to COVID-19 vaccines in people living with HIV; however, these studies did not fully characterize and define that response, both for cellular [where the immune system directly attacks infected cells] and humoral immunity,” says the study senior author Joel Blankson, M.D., Ph.D., professor of medicine at the Johns Hopkins University School of Medicine.

“What we found with the widely used Pfizer/BioNTech vaccine was just the opposite, as it induces robust immune responses in people living with HIV compared to those seen in healthy people.”

CD4+ T lymphocytes, commonly called helper T lymphocytes, were immune system cells that aid another kind of immune response, the B lymphocyte (B cell), react to surfaces protein and antigens on pathogens like SARS-CoV-2.

Immature B cells produce plasma cells, which make an antibody to designate diseased cells for removal from the system, or memory cells, which “learn” the antigen’s molecular composition for a quicker reaction to subsequent illnesses after being triggered by CD4+ T cells. As a result, the CD4+ T cell count can be used to determine how the immunological response reacts to a vaccination that produces humoral resistance.

Blankson and his coworkers collected samples from 12 HIV-positive patients and 17 normal research volunteers within 7 and seventeen days just after the 2nd Pfizer/BioNTech vaccination dosage. There was no indication of previous SARS-CoV-2 illness in these people. All of the HIV patients are on antiretroviral medication, and their CD4+ T lymphocyte counts were 913 cells each microliter on average.

“We found that there was no significant difference in either the vaccine-produced CD4+ T cell responses or the titers [levels] of SARS-CoV-2 spike binding antibodies for healthy participants and those living with HIV,” says Blankson. “This indicates that people living with HIV can be adequately protected against SARS-CoV-2, with proper vaccination.”

The scientists employed assays to identify the existence and assess the concentrations of antibodies towards the proteins that make up the peaks that emerge from the top of a SARS-CoV-2 virus to assess the immune response elicited by the Pfizer/BioNTech vaccination in persons living with HIV. Pfizer/BioNTech & Moderna messenger RNA (mRNA) vaccinations give an individual’s immunological biological instruction to recognize the spikes proteins and begin producing antibodies towards SARS-CoV-2.

More study is warranted, according to Blankson, to see if persons with HIV and lower CD4+ T cell counts have a similar robust immunologic and intracellular response to SARS-CoV-2 vaccinations as the trial subjects.